---
aliases: /news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs
archetype: curated-content
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
categories:
  - 'Symplur: COVID-19'
  - 'Events Taxonomies: Coronavirus Vaccine'
categorySlug:
  - 'symplur: covid-19'
  - 'events taxonomies: coronavirus vaccine'
categoryUrl:
  - topic/symplur-covid-19
  - topic/events-taxonomies-coronavirus-vaccine
categoryLabel:
  - COVID-19
  - Coronavirus Vaccine
contentCategories: netspective-medigy-news-curated-content
institution: null
offering: null
layOut: single
date: '2021-09-06'
description: >-
  Pfizer and Merck &amp; Co. each launched pivotal clinical studies of new
  experimental oral COVID-19 drugs, building on previous work to provide
  outpatient alternatives for patients.Merck is studying w
favIconImage: null
featuredImage:
  alt: 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
  format: JPEG
  href: 735e75aa-ba4f-5c8d-93af-7b1f237ca8e0-featuredImage.jpeg
  size:
    - 364
    - 770
  valid: true
  workPackage: 7667
  wpAttachment:
    fileName: Curated_Featured_Image.jpg
    link: /api/v3/attachments/16755/content
featuredPdf: null
htmlMetaData:
  author: null
  description: Healthcare
  generator: null
  viewport: 'width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0'
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: >-
    Both companies are racing to prove their oral antivirals are effective as
    treatments for COVID-19. Key clinical results could come later this year.
  ogimage: >-
    https://www.healthcaredive.com/user_media/cache/b2/fe/b2fe9be74e8b237f7c9766b5f55e6e67.jpg
  ogsite_name: Healthcare Dive
  ogtitle: 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
  ogtype: article
  ogupdated_time: null
  ogurl: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: aN-77CvDv8Rt4OQnHMaUSm6V87TF8ri5GDUv93p7pHk
  keywords: null
id: 7667
identifier: News
lastMod: '2021-09-06T10:36:34.123025Z'
link:
  brand: healthcaredive.com
  href: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
  original: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
href: >-
  https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
original: >-
  https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
mastHead: NEWS
mdName: 735e75aa-ba4f-5c8d-93af-7b1f237ca8e0.md
openGraphMetaData:
  ogdescription: >-
    Both companies are racing to prove their oral antivirals are effective as
    treatments for COVID-19. Key clinical results could come later this year.
  ogtitle: 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
  ogurl: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
  ogimage: >-
    https://www.healthcaredive.com/user_media/cache/b2/fe/b2fe9be74e8b237f7c9766b5f55e6e67.jpg
  ogsite_name: Healthcare Dive
  ogtype: article
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
  medigyTopics:
    - 'Symplur: COVID-19'
    - 'Events Taxonomies: Coronavirus Vaccine'
  sourceUrl: >-
    https://www.healthcaredive.com/news/pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs/605992/
openProjectWorkPackageType: Curated Content
searchCategory: News
slug: healthcaredive-pfizer-merck-launch-large-new-trials-of-oral-covid-19-drugs
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings:
  - label: Rapid Surge Scheduling
    permalink: /offering/rapid-surge-scheduling
    categories:
      - 'KLAS: Scheduling - Physician'
      - 'Symplur: COVID-19'
    offeringId: 11657
  - label: OSF OnCall Connect
    permalink: /offering/osf-oncall-connect
    categories:
      - 'Symplur: COVID-19'
    offeringId: 11352
  - label: COVID Companion
    permalink: /offering/covid-companion
    categories:
      - 'Symplur: COVID-19'
    offeringId: 11351
  - label: SAS - COVID-19 Data Analytics
    permalink: /offering/sas---covid-19-data-analytics
    categories:
      - 'Symplur: COVID-19'
      - 'Frost & Sullivan: Artificial Intelligence'
      - 'Gartner: Data & Analytics'
    offeringId: 11342
  - label: VigiLanz Vaccinate
    permalink: /offering/vigilanz-vaccinate
    categories:
      - 'Events Taxonomies: Coronavirus Vaccine'
    offeringId: 9724
twitterMetaData:
  twittercard: summary_large_image
  twitterdescription: >-
    Both companies are racing to prove their oral antivirals are effective as
    treatments for COVID-19. Key clinical results could come later this year.
  twittertitle: 'Pfizer, Merck launch large new trials of oral COVID-19 drugs'
  twitterimage: null
  twitterurl: null
---
<ul><li>Pfizer and Merck &amp; Co. each launched pivotal clinical studies of new experimental oral COVID-19 drugs, building on previous work to provide outpatient alternatives for patients.</li><li>Merck is studying whether its medicine, molnupiravir, can prevent COVID-19 in adults who live with a symptomatic patient with a confirmed coronavirus infection. The <a href="https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-3-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection/">trial will include about 1,300 patients</a> who will take molnupiravir or a placebo every 12 hours for five days.</li><li><a href="https://cdn.pfizer.com/pfizercom/2021-09/First_Participant_Dosed_in_Phase_2_3.pdf?xngrygl6i_kDXWrJtM7ixP65qQ6ZXOK0">Pfizer said</a> the first of about 1,140 patients has received a dose of its therapy in a trial to treat symptomatic patients who have not been hospitalized and aren’t at high risk of severe illness. The dosing of the Pfizer treatment — a combination of an older medicine and an experimental drug called PF-07321332 — is also every 12 hours for five days and measured against a placebo.</li></ul>